Accéder au contenu
Merck

Continuous Manufacturing in Oral Solid Dosage

Dissolving tablet representing increased dissolution rates and enhanced solubility of the active ingredient.

Continuous Manufacturing (CM) is a new technology trend in pharmaceutical tablet production which offers many benefits for economics and quality of the products – but challenges as well.

The material handling in CM lines requires specific excipient properties to achieve constant feeding performance, such as good flow and constant quality batch to batch. Excipients with optimal processing properties or excipients tailored for CM often allow to reduce the number of formulation components and, as a result, the number of feeding stations needed. Depending on the selected CM process, direct compressible materials, or materials compatible with twin screw granulation may be needed.

Our portfolio of excipients optimized for excellent performance in solid dose manufacturing processes, suitable for CM, includes:

  • Parteck® LM self-lubricating filler/binder for all tableting processes and suitable for batch and continuous manufacturing processes.
  • Parteck® M mannitol suitable for direct compression, dry granulation, and wet granulation, including twin screw granulation.
  • Parteck® ODT excipient system for fast release and orally disintegrating dosage forms.
  • Parteck® SRP 80 excipient designed for direct compression, enabling controlled release dosage forms.
  • Polyvinyl alcohol 4-88 and particle-optimized quality Parteck® MXP 4-88 polymer as effective binders in continuous twin screw granulation.

All supported by the Emprove® Program with comprehensive documentation to speed up your way to the market. Whenever applicable, our products are compliant with the major pharmacopeias.

Explore how you can improve productivity and performance.



EXPLORE HOW YOU CAN IMPROVE PRODUCTIVITY AND PERFORMANCE

People working at an abstract drug manufacturing system, representing multiple functionalities provided in a single step.

Self-Lubricated Filler-Binder Excipient System for Tableting

Excellent flow properties, consistent dosing, and robust, constant mixing times in continuous and batch processes. Two grades targeting different API dose and lubrication needs.

A pink and purple umbrella protecting a purple molecule from the rain.

Advanced Mannitol for all Tableting Technologies

Particle-optimized mannitol for excellent performance in tableting and rapid release. Two grades available to serve your specific needs in direct compression, wet granulation, roller compaction, and CM approaches such as twin-screw granulation.

A hand holding a purple and pink stopwatch on a yellow background.

Directly Compressible Excipient for ODTs

Produce top quality, rapid acting tablets more cost effectively than ever. Robust tablets, rapid disintegration, excellent mouthfeel combined with superior performance in direct compression and continuous manufacturing.

A clock and a yellow pill, representing a defined release time of the dosage form.

Sustained-Release Solid Dose Formulations

Reliable sustained drug delivery with our functional, polyvinyl alcohol (PVA)-based excipient: suitable for direct compression, reduced risk for dose dumping, robust batch-to-batch consistency ideal for continuous manufacturing.


Related Product Resources


Related Webinars

A digital illustration of a laptop displaying a simplistic human figure next to a pink rectangle, all set against a yellow background.
Continuous Manufacturing: Issues and Answers

In this webinar, you will learn about the key issues in continuous manufacturing concerning excipients and how to address them.

A digital illustration of a laptop displaying a simplistic human figure next to a pink rectangle, all set against a yellow background.
Continuous Manufacturing in Solid Dose: How to Leverage Opportunities of this New Technology

In this webinar, you will learn about the challenging issues of continuous manufacturing, its benefits, and how to address the challenges using excipients.

Connectez-vous pour continuer

Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.

Vous n'avez pas de compte ?